Island Pharma gearing up to start ISLA-101 trial for dengue fever
September 27, 2023 at 04:16 pm
Share
(via NewsDirect)
Island Pharmaceuticals Ltd (ASX:ILA) CEO and managing director Dr David Foster tells Proactive the company is progressing towards a Single Ascending Dose study for its lead asset, ISLA-101, with preparatory work largely complete and key agreements signed. ISLA-101 is a well-known drug candidate that Island is repurposing for the prevention and treatment of dengue and other mosquito-borne diseases. With the Single Ascending Dose study slated to begin next month, Island has now appointed Beyond Drug Development as the Contract Research Organisation to run the study.
Foster said, “We have been focused on moving the Single Ascending Dose study along as quickly as possible and are very pleased to be nearing the commencement point.
"Putting this agreement in place with Beyond as our [Contract Research Organisation] and naming Scientia as our clinical site are key to underpinning the study, with both organisations highly experienced in conducting studies like ours.
“Our focus now turns to pursuing ethics approval. Should all go to plan, we hope to see the first subject dosed in October, and dosing complete in this calendar year, with the study reading out in early 2024.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.